Importantly, new proteasome inhibitors (including Carfilzomib, ONX 0912, MLN 9708, Marizomib), HDAC inhibitors (e.g. Tipifarnib), new IMiDs (Pomalidomide), kinase inhibitors (especially inhibitors of mTOR and HSP90), new immune-based therapies (antibodies against CS-1, CD38, IL-6) and new alkylators (Bendamustine) have proved effective mostly in combination with conventional drugs in phase I and II clinical trials for MM patients who were bortezomib-resistant or in relapse (for reviews see [40, 250, 251]). Here, IL6 is linked to Miyoshi myopathy.